Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Nasser (Lyon, France), S. Larrieu (Bordeaux, France), S. Si-Mohamed (Lyon, France), K. Ahmad (Lyon, France), L. Boussel (Lyon, France), M. Brevet (Lyon, France), L. Chalabreysse (Lyon, France), C. Fabre (Bordeaux, France), S. Marque (Bordeaux, France), D. Revel (Lyon, France), F. Thivolet-Bejui (Lyon, France), J. Traclet (Lyon, France), S. Zeghmar (Lyon, France), D. Maucort-Boulch (Lyon, France), V. Cottin (Lyon, France). A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study. 440

Member's Comments

No comment yet.

Related content which might interest you: Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD) Source: Eur Respir J 2004; 24: Suppl. 48, 533s Year: 2004 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study) Source: Eur Respir J, 57 (2) 2002718; 10.1183/13993003.02718-2020 Year: 2021 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2008; 32: 170-174 Year: 2008 Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 The prevalence of neoplastic transformation in idiopathic pulmonary fibrosis (IPF) lungs. A report from a transplanted IPF population Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis Year: 2011 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014